Vnitr Lek 2011, 57(9):693-696

Prokinetic agents - their contribution to practice of gastroenterology

A. Hep1,*, J. Dolina2
1 Interní gastroenterologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Aleš Hep, CSc.
2 Endoskopické centrum FN Brno, pracoviště Bohunice, přednosta prim. MUDr. Jiří Dolina, Ph.D.

Motility plays a fundamental role in the functioning of the gastrointestinal tract. Prokinetic agents are thus an important treatment modality in patients with functional and certain organ diseases with underlying functional modifications. Gastro-oesophageal reflux disease is frequently associated with a disorder of oesophageal motility, an alteration of gastric evacuation may manifest as an atypical dyspeptic complaint. Prokinetic agents may also be effective in other disease states, such as diabetic gastroparesis, malignant conditions associated with nausea and vomiting, motility disorders in preterm babies etc.

Keywords: functional disorders; prokinetic agents; gastro-oesophageal reflux disease; irritable bowel syndrome; dyspeptic syndrome; motility

Received: July 26, 2011; Published: September 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hep A, Dolina J. Prokinetic agents - their contribution to practice of gastroenterology. Vnitr Lek. 2011;57(9):693-696.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bruley des Varannes S, Coron E, Galmiche JP. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs? Best Pract Res Clin Gastroenterol 2010; 24: 905-921. Go to original source... Go to PubMed...
    2. van Pinxteren B, Sigterman KE, Bonis P et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2010; 11: CD002095. Go to original source... Go to PubMed...
    3. Tosetti C, Bellentani S, Benedetto E et al. The management of patients with new onset of upper gastro-intestinal symptoms in primary care. Dig Liver Dis 2010; 42: 860-864. Go to original source... Go to PubMed...
    4. Tighe MP, Afzal NA, Bevan A et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs 2009; 11: 185-202. Go to original source... Go to PubMed...
    5. Koshino K, Adachi K, Furuta K et al. Effects of mosapride on esophageal functions and gastroesophageal reflux. J Gastroenterol Hepatol 2010; 25: 1066-1071. Go to original source... Go to PubMed...
    6. Bredenoord AJ. New therapies for gastroesophageal reflux disease. Minerva Gastroenterol Dietol 2010; 56: 129-138. Go to PubMed...
    7. Ponce J, Mearin F, Ponce M et al. Symptom profile in gastroesophageal reflux disease in untreated patients and those with persistent symptoms despite treatment. Gastroenterol Hepatol 2010; 33: 271-279. Go to original source... Go to PubMed...
    8. Donnellan C, Preston C, Moayyedi P et al. WITHDRAWN: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2010; 2: CD003245. Go to original source... Go to PubMed...
    9. Miwa H, Inoue K, Ashida K et al. Japan TREND study group. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease - a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 323-332. Go to original source... Go to PubMed...
    10. Futagami S, Iwakiri K, Shindo T et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol 2010; 45: 413-421. Go to original source... Go to PubMed...
    11. Hammer HF. Reflux-associated laryngitis and laryngopharyngeal reflux: a gastroenterologist's point of view. Dig Dis 2009; 27: 14-17. Go to original source... Go to PubMed...
    12. Mirbagheri SA, Sadeghi A, Amouie M et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci 2008; 53: 2621-2626. Go to original source... Go to PubMed...
    13. Ciovica R, Riedl O, Neumayer C et al. The use of medication after laparoscopic antireflux surgery. Surg Endosc 2009; 23: 1938-1946. Go to original source... Go to PubMed...
    14. Kandulski A, Venerito M, Malfertheiner P. Therapeutic strategies for the treatment of dyspepsia. Expert Opin Pharmacother 2010; 11: 2517-2525. Go to original source... Go to PubMed...
    15. Brun R, Kuo B. Functional dyspepsia. Therap Adv Gastroenterol 2010; 3: 145-164. Go to original source... Go to PubMed...
    16. Miwa H, Watari J, Fukui H et al. Pathogenesis and management of functional dyspepsia. Nippon Rinsho 2010; 68: 1391-1401.
    17. Miyamoto M, Manabe N, Haruma K. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy. Intern Med 2010; 49: 1469-1476. Go to original source... Go to PubMed...
    18. Holtmann G, Gapasin J. Failed therapy and directions for the future in dyspepsia. Dig Dis 2008; 26: 218-224. Go to original source... Go to PubMed...
    19. Gasbarrini G, Merra G, Candelli M et al. Evaluation of gastric emptying and gastrointestinal symptoms in dyspeptic patients before and after hydropinic therapy. Recenti Prog Med 2010; 101: 389-392.
    20. Tack J, Blondeau K, Boecxstaens V et al. Review article: the pathophysiology, differential diagnosis and management of rumination syndrome. Aliment Pharmacol Ther 2011; 33: 782-788. Go to original source... Go to PubMed...
    21. Al Samaraee A, McCallum IJ, Coyne PE et al. Nutritional strategies in severe acute pancreatitis: a systematic review of the evidence. Surgeon 2010; 8: 105-110. Go to original source... Go to PubMed...
    22. Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol 2010; 25: 691-699. Go to original source... Go to PubMed...
    23. Barkun AN, Bardou M, Martel M et al. Prokinetics in acute upper GI bleeding: a meta-analysis. Gastrointest Endosc 2010; 72: 1138-1145. Go to original source... Go to PubMed...
    24. Ducrotté P. Abdominal bloating: an up-to-date. Gastroenterol Clin Biol 2009; 33 (10-11 Suppl): F94-F100. Go to original source... Go to PubMed...
    25. Bielefeldt K, Raza N, Zickmund SL. Different faces of gastroparesis. World J Gastroenterol 2009; 15: 6052-6060. Go to original source... Go to PubMed...
    26. Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf 2010; 5: 105-111. Go to original source... Go to PubMed...
    27. Ionescu D, Iancu C, Ion D et al. Implementing fast-track protocol for colorectal surgery: a prospective randomized clinical trial. World J Surg 2009; 33: 2433-2438. Go to original source... Go to PubMed...
    28. Cresi F, Marinaccio C, Russo MC et al. Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. J Perinatol 2008; 28: 766-770. Go to original source... Go to PubMed...
    29. Kashyap P, Farrugia G. Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years. Gut 2010; 59: 1716-1726. Go to original source... Go to PubMed...
    30. Reddymasu SC, McCallum RW. Small intestinal bacterial overgrowth in gastroparesis: are there any predictors? J Clin Gastroenterol 2010; 44: e8-e13. Go to original source... Go to PubMed...
    31. Gupta A, Dhiman RK, Kumari S et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010; 53: 849-855. Go to original source... Go to PubMed...
    32. Shaikh N, Kettern MA, Hanssens Y et al. A rare and unsuspected complication of Clostridium difficile infection. Intensive Care Med 2008; 34: 963-966. Go to original source... Go to PubMed...
    33. Reddymasu SC, Lin Z, Sarosiek I et al. Efficacy of gastric electrical stimulation in improving functional vomiting in patients with normal gastric emptying. Dig Dis Sci 2010; 55: 983-987. Go to original source... Go to PubMed...
    34. Lanuti M, Dedelva P, Morse CR et al. Management of Delayed Gastric Emptying After Esophagectomy With Endoscopic Balloon Dilatation of the Pylorus. Ann Thorac Surg 2011; 91: 1019-1024. Go to original source... Go to PubMed...
    35. Bishop S, Young H, Goldsmith D et al. Bowel motions in critically ill patients: a pilot observational study. Crit Care Resusc 2010; 12: 182-185. Go to original source... Go to PubMed...
    36. Lam HS, Ng PC. Use of prokinetics in the preterm infant. Curr Opin Pediatr 2011; 23: 156-160. Go to original source... Go to PubMed...
    37. Fujii T, Nakabayashi T, Hashimoto S et al. Successful perioperative management of patients with Parkinson's disease following gastrointestinal surgery: report of three cases. Surg Today 2009; 39: 807-810. Go to original source... Go to PubMed...
    38. Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases. Clin Evid (Online) 2009; pii: 2406.
    39. Min BH, Son HJ, Kim JJ et al. Idiopathic proximal hemimegacolon: radiologic findings and analyses of clinical and physiological characteristics. Abdom Imaging 2010; 35: 291-295. Go to original source... Go to PubMed...
    40. Di Saverio S, Catena F, Ansaloni L et al. Water-soluble contrast medium (gastrografin) value in adhesive small intestine obstruction (ASIO): a prospective, randomized, controlled, clinical trial. World J Surg 2008; 32: 2293-2304. Go to original source... Go to PubMed...
    41. Almeida N, Figueiredo P, Freire P et al. The effect of metoclopramide in capsule enteroscopy. Dig Dis Sci 2010; 55: 153-157. Go to original source... Go to PubMed...
    42. Chourasia D, Misra A, Pandey R et al. Gastric atrophy and intestinal metaplasia in a patient on long-term proton pump inhibitor therapy. Trop Gastroenterol 2008; 29: 172-174. Go to PubMed...
    43. Postgate A, Tekkis P, Patterson N et al. Are bowel purgatives and prokinetics useful for small-bowel capsule endoscopy? A prospective randomized controlled study. Gastrointest Endosc 2009; 69: 1120-1128. Go to original source... Go to PubMed...
    44. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol 2008; 8: 690-696. Go to original source... Go to PubMed...
    45. Taylor SJ, Manara AR, Brown J. Treating delayed gastric emptying in critical illness: metoclopramide, erythromycin, and bedside (cortrak) nasointestinal tube placement. JPEN J Parenter Enteral Nutr 2010; 34: 289-294. Go to original source... Go to PubMed...
    46. Kim KH, Kim TH, Choi JY et al. Acupuncture for symptomatic relief of gastroparesis in a diabetic haemodialysis patient. Acupunct Med 2010; 28: 101-103. Go to original source... Go to PubMed...
    47. Arai K, Takeuchi Y, Watanabe H et al. Prokinetics influence the pharmacokinetics of rabeprazole. Digestion 2008; 78: 67-71. Go to original source... Go to PubMed...
    48. Lee TH, Choi JJ, Kim DH et al. Gastroprokinetic effects of DA-9701, a new prokinetic agent formulated with Pharbitis Semen and Corydalis Tuber. Phytomedicine 2008; 15: 836-843. Go to original source... Go to PubMed...
    49. Takanashi H, Cynshi O. Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis. Regul Pept 2009; 155: 18-23. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.